Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zosano Pharma has closed enrollment for its Phase II clinical trial evaluating a parathyroid hormone transdermal microprojection delivery system to treat post menopausal women with osteoporosis who are at a high risk of bone fracture.
Subscribe to our email newsletter
This enrollment was completed ahead of schedule. The results from the trial are expected to be available in the second half of 2008. The company said that this Macroflux transdermal microprojection delivery system provides unique benefits, including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.
Cory Zwerling, Zosano’s CEO and president, said: “Closing enrollment early is an important milestone for Zosano. This achievement reflects positively on physician and patient acceptance of our parathyroid hormone delivery system.”